产品详情
简单介绍：
Anti-N4BP2L2/PFAAP5抗体产品质量稳定，实验效果明显，货期快，价格优惠，欢迎垂询订购！我公司长期供应**组化抗体、WB抗体、**组化试剂盒和抗体试验所需全部相关试剂、荧光标记抗体、单克隆抗体、多克隆抗体、各种标记的二抗IgG/IgM/IgD/IgA等科研实验抗体。Anti-N4BP2L2/PFAAP5抗体用于**组化实验,WB实验,相应的标记抗体有HRP标记抗体,FITC标记,BIO等。
详情介绍：
Rabbit Anti-N4BP2L2/PFAAP5
Cat. Number:
Anti-N4BP2L2/PFAAP5抗体KL-18986R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
PFAAP5 is a 583 amino acid nuclear protein that potentially is involved in transcriptional regulation. PFAAP5 is phosphorylated on Ser 199 in response to DNA damage, probably by ATM or ATR. Primarily expressed in bone marrow, PFAAP5 is dramatically down-regulated after exposure to arsenic compounds, an event which precedes neutropenia. PFAAP5 interacts with both Gfi-1 and Neutrophil Elastase, twoAnti-N4BP2L2/PFAAP5抗体 proteins that are implicated in neutropenia disorders. Defects in the gene encoding Neutrophil Elastase, ELA2, are the cause of cyclic haematopoiesis, which, with decreased numbers of circulating neutrophils, leads to an increased risk for opportunistic infection. Gfi1 is a transcriptional repressor that targets the ELA2 gene among others. With PFAAP5 expression, Neutrophil Elastase can potentiate repression of Gfi1 target genes, leading to the transcription of ELA2 and subsequent neutrophil differentiation. There are two isoforms of PFAAP5 that are produced as a result of alternative splicing events.
Also known as:
92M18.3 (novel protein); 92M18.3; Anti-N4BP2L2/PFAAP5抗体CG005; CG016; FLJ36195; FLJ41089; FLJ43077; N4BP2L2; NEDD4 binding protein 2 like 2; PFAAP5; Phosphonoformate immuno associated protein 5; Protein from BCRA2 region.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, .
●
Immunogen: KLH conjugatedAnti-N4BP2L2/PFAAP5抗体 synthetic peptide derived from human N4BP2L2/PFAAP5.
●
Predicted Molecular Weight: 67kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 Anti-N4BP2L2/PFAAP5抗体
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
